Go Back
Ovid Therapeutics Inc. reports $1.3 billion Q1 loss
By USInMinutes - May 05, 2023, 12:26 PM ET
Last Updated - Jul 18, 2023, 03:38 PM EDT
The company generated $66.20 million in quarterly revenue
Ovid Therapeutics Inc. [OVID] has reported fiscal Q1 loss of $1.30 billion.
On a per-share basis, the DE based company said its diluted earnings are $0.19.
The Pharmaceutical Preparations firm posted revenue of $66.20 million in this period.
Also Read:
- Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
- Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of ...
- Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
- Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in ...
- Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
NewsInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to news alerts here.
Sponsored
Sponsored
Read More from Investing
Popular News
Latest News